Home › Hyperlipidemias › NCT05103254
Bempedoic Acid Pregnancy Surveillance Program
RecruitingObservational study
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome Exclusion Criteria:
About the study
Bempedoic acid pregnancy surveillance program
What is being tested
- Bempedoic Acid (drug)
- Bempedoic Acid / Ezetimibe (drug)
Sponsor: Esperion Therapeutics, Inc. · Participants: 20 · Started: Sep 1, 2021
Contact the study team
- Esperion Therapuetics · Phone: 1 833 377 7633 (Option 5)
Official record on ClinicalTrials.gov — NCT05103254
Locations in the U.S.
| North Carolina | Evidera, PPD business unit, Morrisville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.